RIGL · Rigel Pharmaceuticals Inc · Executive Compensation
$47.15
+0.18 (+0.38%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$900.00M
Shares
18.68M
Volume · Oct 2
185.67K
Avg daily vol (3M)
301.34K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Raul Rodriguez | President and Chief Executive Officer | $2,998,688 |
| David Santos | Executive Vice President and Chief Commercial Officer | $1,382,463 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | $1,377,793 |
| Raymond Furey | Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $1,324,589 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Raul Rodriguez | President and Chief Executive Officer | $3,440,790 |
| David Santos | Executive Vice President and Chief Commercial Officer | $1,341,791 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | $1,210,005 |
| Raymond Furey | Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $683,000 |
| Lisa Rojkjaer | Executive Vice President and Chief Medical Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Raul Rodriguez | President and Chief Executive Officer | $2,864,120 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | $1,139,450 |
| David Santos | Executive Vice President and Chief Commercial Officer | $1,124,415 |
| Raymond Furey | Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $342,283 |
| Lisa Rojkjaer | Executive Vice President and Chief Medical Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Raul Rodriguez | President and Chief Executive Officer | $2,963,884 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | $1,202,524 |
| Dolly Vance | Executive Vice President, Corporate Affairs, General | $1,194,583 |
| David Santos | Executive Vice President and Chief Commercial Officer | $1,190,602 |
| Wolfgang Dummer | M.D., Ph.D. Executive Vice President and Chief Medical Officer | $730,439 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Raul Rodriguez | President and Chief Executive Officer | $2,562,118 |
| Dolly Vance | Executive Vice President, Corporate Affairs, General | $1,181,962 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | $1,033,216 |
| Eldon C. Mayer | III\ Executive Vice President, Chief Commercial Officer | $933,614 |
| Esteban Masuda | Executive Vice President, Research Anne-Marie Duliege\ | $796,088 |
| Wolfgang Dummer | M.D., Ph.D. Executive Vice President and Chief Medical Officer | $779,095 |
| David Santos | Executive Vice President and Chief Commercial Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Raul Rodriguez | President and Chief Executive Officer | $3,980,860 |
| Dolly Vance | Executive Vice President, Corporate Affairs, General | $1,770,828 |
| Eldon C. Mayer | III\ Executive Vice President, Chief Commercial Officer | $1,584,252 |
| Esteban Masuda | Executive Vice President, Research Anne-Marie Duliege\ | $1,300,238 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | $1,194,161 |
| Wolfgang Dummer | M.D., Ph.D. Executive Vice President and Chief Medical Officer | — |
| David Santos | Executive Vice President and Chief Commercial Officer | — |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Raul Rodriguez | President and Chief Executive Officer | $2,172,790 |
| Corporate Affairs | General | $1,130,060 |
| Eldon C. Mayer | III\ Executive Vice President, Chief Commercial Officer | $712,036 |
| Esteban Masuda | Executive Vice President, Research Anne-Marie Duliege\ | $638,378 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | — |
| Wolfgang Dummer | M.D., Ph.D. Executive Vice President and Chief Medical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lisa Rojkjaer, M.D. | Executive Vice President and Chief Medical Officer | Resigned | 2026-07-01 |
| Alison L. Hannah, M.D. | member of the Board of Directors | Resigned | 2026-07-01 |
| Alison L. Hannah, M.D. | Executive Vice President and Chief Medical Officer | Appointed | 2026-07-01 |
| Raul Rodriguez | Director | Appointed | 2026-05-20 |
| Walter Moos, Ph.D. | Director | Appointed | 2026-05-20 |
| Alison Hannah, M.D. | Director | Appointed | 2026-05-20 |
| Michael P. Miller | director | Appointed | 2026-02-03 |
| Jane Wasman | director | Appointed | 2025-05-23 |
| Kamil Ali-Jackson | director | Appointed | 2025-05-23 |
| Mark J. Frohlich | board of directors | Appointed | 2025-03-10 |
| Dr. Brian Kotzin | member of the Board of Directors | Resigned | 2024-09-19 |
| Raul R. Rodriguez | Director | Appointed | 2023-05-30 |
| Walter H. Moos | Director | Appointed | 2023-05-30 |
| Alison L. Hannah | Director | Appointed | 2023-05-30 |
| Wolfgang Dummer, M.D., Ph.D. | Executive Vice President and Chief Medical Officer | Resigned | 2023-02-03 |
| Dolly A. Vance | general counsel, executive vice president, corporate affairs, and corporate secretary | Retired | 2022-10-11 |